After a spray of Spravato, patients often experience sleepiness, dizziness, breathing problems, or feelings of disconnection, which tend to peak at 40 minutes and fade after about two hours. The spray may also impair judgment, thinking, reaction speed, and motor skills, which means patients should not operate machinery until the following day.
Spravato isn't perfect, but it is the first new medication for major depression approved by the FDA in decades.